BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

Figure 1A: **Retention of Activity by PEGylated *Candida* Uricase**



#12

Figure 1B: **Retention of Activity by PEGylated *Candida* Uricase**



Figure 2A: **Retention of Activity by PEGylated Porcine Uricase**



Figure 2B: **Retention of Activity by PEGylated Porcine Uricase**



Figure 3A: **Retention of Activity by PEGylated PBC Uricase**



Figure 3B: **Retention of Activity by PEGylated PBC Uricase**



Figure 4A:

Retention of Activity by PEGylated Uricozyme® (*A. flavus* Uricase)



Figure 4B:

Retention of Activity by PEGylated Uricozyme® (*A. flavus* Uricase)



Figure 5A: **Retention of Activity by PEGylated Soybean Uricase**



Figure 5B: **Retention of Activity by PEGylated Soybean Uricase**



Figure 6: Deduced amino acid sequences of **Pig-Baboon Chimeric (PBC)** uricase, PBC uricase that is truncated at the amino and carboxyl terminals (**PBC-NT-CT**) and Porcine uricase containing the mutations R291**K** and T301**S** (**PKS** Uricase) (SEQ ID NO:3), compared with the porcine sequence (SEQ ID NO: 1) and baboon sequence (SEQ ID NO: 2)

Porcine	MAHYRNDYKK NDEVEFVRTG YGKDMIKVLH IQRDGKYHSI	40
PBC	*porcine sequence 1-225 →*	40
PBC-NT-CT	*porcine sequence 1-219 →*	34
PKS	*porcine sequence 1-288 →*	40
Baboon	MA**D**Y**H**N**N**YKK NDEL**E**FVRTG YGKDM**V**KVLH IQRDGKYHSI	40
Porcine	KEVATSVQLT LSSKKDYLHG DNSDVIPTDT IKNTVNVLAK	80
PBC	*porcine sequence →*	80
PBC-NT-CT	*porcine sequence →*	74
PKS	*porcine sequence →*	80
Baboon	KEVATSVQLT LSSKKDYLHG DNSD**I**IPTDT IKNTV**H**VLAK	80
Porcine	FKGIKSIETF AVTICEHFLS SFKHVIRAQV YVEEVPWKRF	120
PBC	*porcine sequence →*	120
PBC-NT-CT	*porcine sequence →*	114
PKS	*porcine sequence →*	120
Baboon	FKGIKSI**EAF** **GVNI**CE**Y**FLS SF**N**HVIRAQV YVEE**I**PWKR**L**	120
Porcine	EKNGVKHVHA FIYTPTGTHF CEVEQIRNGP PVIHSGIKDL	160
PBC	*porcine sequence →*	160
PBC-NT-CT	*porcine sequence →*	154
PKS	*porcine sequence →*	160
Baboon	EKNGVKHVHA FI**H**TPTGTHF CEVEQ**L**R**S**GP PVIHSGIKDL	160
Porcine	KVLKTTQSGF EGFIKDQFTT LPEVKDRCFA TQVYCKWRYH	200
PBC	*porcine sequence →*	200
PBC-NT-CT	*porcine sequence →*	194
PKS	*porcine sequence →*	200
Baboon	KVLKTTQSGF EGFIKDQFTT LPEVKDRCFA TQVYCKWRYH	200
Porcine	QGRDVDFEAT WDTVRSIVLQ KFAGPYDKGE YSPSVQKTLY	240
PBC	*porcine sequence → ← baboon sequence*	240
PBC-NT-CT	*porcine sequence → ← baboon sequence*	234
PKS	*porcine sequence →*	240
Baboon	QCRDVDFEAT **WGTIRDLVLE** KFAGPYDKGE YSPSVQKTLY	240
Porcine	DIQVLTLGQV PEIEDMEISL PNIHYLNIDM SKMGLINKEE	280
PBC	*baboon sequence →*	280
PBC-NT-CT	*baboon sequence →*	274
PKS	*porcine sequence →*	280
Baboon	DIQVL**SL**S**R**V PEIEDMEISL PNIHY**F**NIDM SKMGLINKEE	280
Porcine	VLLPLDNPYG RITGTVKRKL TSRL	304
PBC	*baboon sequence →*	304
PBC-NT-CT	*baboon sequence →*	295
PKS	*porcine ← baboon →*	304
Baboon	VLLPLDNPYG **K**ITGTVKRKL **S**SRL	304

Figure 7: **Serum Uricase Activity 24 Hours after Each PEG-Uricase Injection, Relative to the First Injection**



Figure 8: **Inverse Relationship between Serum PEG-Uricase Activity and Uric Acid Levels in the Serum and Urine of a Uricase-Deficient Mouse**



Figure 9: **Decreased Severity of Urine-Concentrating Defect in Uricase-Deficient Mice Treated with PEG-Uricase**



Figure 10: **Decreased Severity of Nephrogenic Diabetes Insipidus in Uricase-Deficient Mice Treated with PEG-Uricase**



Figure 11:

Decreased S v rity of Uric Acid-Induced Nephropathy aft r Tr atment with PEG-Uricase, as Visualized by Magnetic Resonanc Microscopy



Figure 12: **Clearance from the Circulation of BALB/c Mice of PBC Uricase Tetramer and Octamer Coupled to 5-6 Strands of 10-kDa PEG/Subunit**